Focused On-demand Library for Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 4

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

P0C6T2

UPID:

OST4_HUMAN

Alternative names:

Alternative UPACC:

P0C6T2

Background:

Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 4 plays a crucial role in the process of N-glycosylation, a fundamental biochemical pathway that modifies proteins and affects their stability, folding, and function. This protein is a part of the oligosaccharyl transferase (OST) complex, essential for transferring glycan groups to nascent proteins in the endoplasmic reticulum, a step critical for proper protein maturation and function.

Therapeutic significance:

Understanding the role of Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 4 could open doors to potential therapeutic strategies. Its involvement in protein N-glycosylation, a process integral to protein stability and function, highlights its potential as a target for therapeutic intervention in diseases where protein misfolding or dysfunction is a factor.